Medical communications turns evidence into credible scientific exchange. Pharma marketing turns an approved brand strategy into compliant demand generation.
A medical communications agency is usually the better fit when science leads the brief: medical affairs, KOL engagement, publications, congresses or HCP education. A pharma marketing agency is usually the better fit when the work is driven by positioning, campaign planning, brand activation, patient support, sales enablement or digital performance. In UK pharma, the useful distinction is not “science versus creativity”. It is who owns the objective, who signs off the claim, and whether the output is promotional, non-promotional, educational or sitting somewhere awkward in between.
| Decision point | Choose med-comms when… | Choose pharma marketing when… |
|---|---|---|
| Primary owner | Medical affairs, scientific affairs or publications leads the brief | Brand, commercial or omnichannel leads the brief |
| Core job | Explain evidence accurately and credibly | Build awareness, preference and action |
| Main risk | Scientific imbalance, over-interpretation, weak referencing | Promotion, claims, audience access, brand compliance |
| Typical outputs | Advisory boards, congress content, medical education, publications, MSL materials | Campaign platforms, HCP campaigns, websites, sales aids, CRM journeys |
Where Med-Comms Fits In A Pharma Team
Med-comms sits closest to the scientific story: what the data supports, what clinicians need to understand, and how medical affairs can exchange information without drifting into promotion. Its strongest role is turning complex clinical, real-world or health-economic evidence into material that can stand up to expert scrutiny.
In practice, that might be a congress symposium, advisory board stimulus, publication plan, field medical slide deck, disease education module, MSL training, KOL mapping, scientific narrative or HCP education programme. The output may look polished, but the first question is usually “is this scientifically accurate and balanced?” rather than “will this convert?”
That distinction matters in the UK because the ABPI Code of Practice for the Pharmaceutical Industry 2024 covers promotion of prescription medicines to health professionals and relevant decision makers, as well as standards for information provided to the public, patients and patient organisations. The PMCPA administers the ABPI Code independently of the ABPI. So med-comms teams need to think beyond the manuscript or slide deck itself and consider how a scientific education asset may be interpreted once a company sponsors, commissions, hosts or distributes it.
A strong medical communications agency will ask for the study design, licence status, summary of product characteristics, claims matrix, references, intended audience and dissemination route before it starts writing. If the first conversation is about taglines, it is probably not operating as a serious med-comms partner.
Where Promotional Pharma Marketing Fits
Pharma marketing sits closest to the brand job: market definition, positioning, audience segmentation, channel strategy, campaign ideas, sales enablement and measurable activation. The agency is still working inside a regulated environment, but the brief is explicitly connected to uptake, launch momentum, share of voice, HCP engagement or patient support.
That can include a brand platform, core visual aid, HCP website, email journey, paid media plan, congress booth, leavepiece, rep-triggered email, patient support journey, market access explainer or omnichannel measurement plan. The best pharma marketing agencies do not treat compliance as a final proofreading step. They build the claim hierarchy, modular content plan and review assumptions before creative development begins.
The MHRA Blue Guide, updated on 28 March 2025, is the central UK guidance for advertising and promotion of medicines. For prescription medicines, the ABPI Code also applies online when promotional material is directed to a UK audience. That is why a “digital-first” pharma campaign is not just a healthcare-flavoured version of B2B SaaS marketing. Audience gating, prescribing information, claim substantiation and separation of public and HCP content are design constraints, not admin details.
The practical test is simple. If the asset needs to persuade a specific audience to remember, ask, prescribe, recommend, refer, enrol or act, you are in pharma marketing territory. If the asset needs to explain the science so the audience can make an informed professional judgement, you are closer to med-comms.
The Review Workflow Is The Real Difference
The fastest way to choose the wrong agency is to compare portfolios and ignore review workflows. In UK pharma, a clever idea that cannot pass medical, legal and regulatory review is not really an idea. It is a delay with a moodboard.
The ABPI Code’s Clause 8 on certification and examination says promotional material must not be issued unless its final form has been certified by an appropriate signatory, and that the certifier must not be the person responsible for developing or drawing up the material. The same clause also covers examination or certification of several non-promotional materials, including patient education material related to diseases or medicines, patient organisation materials, collaborative working materials and non-interventional study protocols.
That makes workflow design part of the creative brief. A med-comms partner should build reference packs, annotation discipline and version control around scientific accuracy. A pharma marketing partner should build claim architecture, modular approval, audience segmentation and channel governance around promotional risk.
| Workflow area | Med-comms strength | Pharma marketing strength | Failure mode if ignored |
|---|---|---|---|
| Claims | Evidence interpretation, balance, limitations | Claim hierarchy, message testing, channel adaptation | Claims become either too cautious to be useful or too promotional to approve |
| Review file | Full references, annotations, author history | Asset map, final form, channel variants, prescribing information | Reviewers see fragments and reopen decisions repeatedly |
| Audience | KOLs, HCP education, medical affairs stakeholders | HCP segments, patients, carers, payers, sales teams | Public/HCP separation becomes unclear |
| Measurement | Knowledge, confidence, engagement quality | Reach, frequency, action, conversion, sales enablement | The team measures activity rather than behaviour |
Two operational facts are worth keeping on the table. First, certificates and final-form material must be preserved for at least three years after final use or event date under ABPI Clause 8.6. Second, material still in use must be recertified at intervals of no more than two years under Clause 8.5. These are not abstract compliance points. They shape naming conventions, archive ownership, modular content refreshes and who can answer a regulator’s question long after launch.
Internal medical/legal/regulatory review timing varies by company, asset type, signatory availability and whether the claim file is ready. A launch campaign with repeated review rounds can still lose weeks if the agency writes first and annotates later. The better operating model reverses that sequence: define the claim ladder, review assumptions and source hierarchy before creative exploration.
Brand Strategy, Medical Affairs And The Grey Zone
The hardest projects are rarely pure med-comms or pure marketing. They are the grey-zone programmes: disease awareness, pre-launch education, congress ecosystems, KOL engagement, patient support, market shaping, and medical education around a therapy area where the company also has a commercial interest.
This is where labels stop helping. You need to identify the dominant intent.
If the dominant intent is to improve understanding of a disease, unmet need, pathway, study design or clinical decision point, med-comms should lead and marketing should support channel design. If the dominant intent is to build brand salience, drive HCP action or move a target segment through a journey, pharma marketing should lead and medical should set the evidence boundaries.
For example, an HCP education hub about a disease area may be non-promotional in concept, but the risk changes if it sits beside brand content, uses sales-force distribution, favours a pathway aligned with one product, or collects data for later promotional retargeting. Conversely, a promotional brand campaign still needs scientific discipline if its differentiation depends on endpoint interpretation, safety nuance, administration burden or patient type.
The mistake is letting either discipline work alone. Med-comms-only teams can produce accurate assets that nobody uses. Marketing-only teams can produce clear campaigns that spend weeks in review because the science was under-built.
The Teapot Decision Framework
Use this framework before you brief anyone. It is deliberately practical because most agency selection mistakes happen before the first proposal is written.
| Question | If the answer is “mostly scientific” | If the answer is “mostly behavioural” |
|---|---|---|
| What is the primary risk? | Misrepresenting data, omitting balance, weak references | Over-promotion, wrong audience, unclear action |
| Who should own the brief? | Medical affairs or scientific communications | Brand, commercial, omnichannel or patient engagement |
| What is the core artefact? | Scientific platform, education plan, publication or congress asset | Campaign platform, journey, sales asset or digital experience |
| Who must be involved early? | Medical signatory, publications, KOL lead, MSL leadership | Brand lead, regulatory reviewer, channel owner, analytics lead |
| What proves success? | Improved understanding, expert confidence, quality of engagement | Qualified reach, engagement, action, conversion or field adoption |
Then apply the four-gate test:
- Intent gate: Is the goal education, exchange, awareness, behaviour change or brand preference?
- Audience gate: Is the content for HCPs, patients, public audiences, payers, internal teams or mixed audiences?
- Evidence gate: Are the central claims based on published data, approved product information, company analysis or future-looking strategy?
- Distribution gate: Will the content be used by medical, sales, paid media, owned channels, congress teams or third-party faculty?
If two or more gates point to medical affairs, lead with med-comms. If two or more point to promotion or action, lead with pharma marketing. If the gates split evenly, choose an integrated team with one accountable strategist and separate medical and promotional review tracks.
For broader regulated-category support, see our pharma marketing work. If you already know the asset type and need help mapping ownership, review and content architecture, contact Teapot.
When This Is Not For You
This comparison is not for you if you are trying to outsource regulatory responsibility to an agency. The marketing authorisation holder and sponsoring company still own the risk, even when a third party drafts the material.
It is also not for you if your internal signatories are unavailable until final review. No agency model fixes a process where medical, legal and regulatory teams first see the strategic assumptions after the creative route has already been sold internally.
One uncomfortable line: if your team cannot define whether a programme is promotional or non-promotional, you may need a compliance workshop before you need an agency pitch. That may slow the project down for a week, but it can save months of rework.
You may not need a specialist med-comms partner if the task is a narrow media buy, a corporate employer-branding campaign, a patient recruitment landing page with no medicine claims, or a simple production adaptation from an already approved master asset. You may not need a pharma marketing agency if the task is a manuscript, advisory board report, evidence gap analysis or internal MSL scientific training module.
FAQ
Is a medical communications agency the same as a healthcare marketing agency?
No. A medical communications agency is usually science-led and focused on medical affairs, HCP education, publications, congresses and evidence communication. A healthcare or pharma marketing agency is usually brand-led and focused on strategy, campaigns, activation and measurable audience behaviour. Some agencies do both, but the review workflow should still separate scientific exchange from promotion.
Can one agency handle both med-comms and pharma marketing?
Yes, if it has distinct medical writing, strategy, creative, regulatory-aware project management and channel planning capabilities. The risk is a blended team that treats every asset as “content”. Ask who owns scientific accuracy, who owns promotional claims, who prepares annotations and who manages final-form certification evidence.
Which agency should lead HCP education?
For independent-feeling disease education, congress learning or medical affairs programmes, med-comms should usually lead. For branded HCP campaigns, rep-enabled materials or product-linked journeys, pharma marketing should usually lead with strong medical input. The deciding factor is intent and distribution, not whether the audience is an HCP.
What should a UK pharma brief include before agency selection?
Include audience, market, licence status, intended use, promotional or non-promotional classification, core evidence, claim boundaries, review process, signatory availability, required channels, timelines, measurement plan and archive expectations. If those details are missing, proposals may look creative, but they will not be comparable.
